|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| Beyond PSMA - New Targets in Prostate Cancer
|
| Tanya Dorff, MD
|
| Tanya Dorff joins Alicia Morgans to discuss the highlights from her presentation at the 2022 GU ASCO Annual Meeting focusing on new targets in prostate cancer beyond prostate-specific membrane antigen (PSMA).
|
|
|
|
|
|
|
|
|
|
|
|
| CAR T and Cellular-Based Therapies |
Vivek Narayan, MD, MS
Vivek Narayan joins Alicia Morgans at ASCO 2022 to discuss his work with CAR T-cell therapies and prostate cancer, the first-in-human study. Using a low-dose escalation approach, Dr. Narayan and his team designed the study safety as the primary objective to evaluate the feasibility of manufacturing and delivering the CAR T-cells. |
|
|
|
|
|
|
|
|
|
|
| Future Targets for Cellular Therapy in Prostate Cancer |
| Vivek Narayan, MD, MS |
| In his portion of this case-based discussion, Dr. Vivek Narayan discusses some of the barriers to the efficacy of CAR-T therapies. These include limited T-cell expansion or persistence once infused, dysfunction of infused T-cells, tumor immune escape by down-regulation of the targeted tumor antigen, and inflammatory toxicities such as CRS or neurotoxicity. |
|
|
|
|
|
| Phase 1 Study of P-PSMA-101 CAR T-Cells in Patients With Metastatic Castration-Resistant Prostate Cancer
|
| Susan F. Slovin MD, PhD, FACP
|
| Susan Slovin presents a poster on a phase 1 trial examining the use of P-PSMA-101, a chimeric antigen receptor T (CART) therapy targeting PSMA for men with advanced prostate cancer. P-PSMA-101 is an autologous CAR-T therapy targeting PSMA, with a high percentage of stem cell memory T cells (TSCM) associated with efficacy, safety, and bone homing (particularly relevant to prostate cancer).
|
|
|
|
|
|
|
|
|
|
|
| Phase 1 study of PSCA-targeted CAR T-Cell therapy for mCRPC |
| Tanya Dorff, MD |
| Tanya Dorff presents the results of their phase 1 study assessing PSCA-targeted CAR T cell therapy for mCRPC. CAR-engineered T cell therapies are being pursued for the treatment of mCRPC. Prostate Stem Cell Antigen (PSCA) is highly expressed on the surface membrane in mCRPC and with limited expression on normal tissues. |
|
|
|
|
|
| T-cell Redirection in Advanced Prostate Cancer to Prevent Cancer Progression and Death - Discussion |
| David James VanderWeele, MD, Ph.D. |
| David VanderWeele lays the groundwork for a discussion primarily around T-cell redirection in advanced prostate cancer to prevent cancer progression and death. This is an interesting and important topic as immunotherapy has not been as effective in prostate cancer as opposed to other solid tumor malignancies. There are putative tumor antigens in prostate cancers that could be exploited for immunotherapy purposes. |
|
|
|
|
|
| Safety and Early Efficacy Results From a Phase 1, Multicenter Trial of PSMA-Targeted Armored CAR T-Cells in Patients With Advanced mCRPC
|
| Meredith McKean MD
|
| Meredith McKean presents a poster focused on the role of chimeric antigen receptor T (CART)-cells in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) based on the CART-PSMA-02 trial, a multi-center, open-label, phase 1 trial.
|
|
|
|
|
|
| CAR-T for Prostate Cancer: Current Strategies to Improve Efficacy
|
| Tanya B. Dorff, MD
|
| In her portion of this case-based panel, Dr. Dorff described chimeric antigen receptor T-cell (CAR-T) therapy and its potential use in prostate cancer. She indicated that CAR-Ts are especially exciting given their potential to induce long-term disease responses, such as have been seen in leukemias and lymphomas. CAR-T cells are a flexible platform, where in addition to introducing a chimeric receptor against a tumor antigen into T-cells, they can be engineered to have immune-co-stimulatory domains and even secrete cytokines to help support T-cell proliferation.
|
|
|
|
|
|
 |
